Ubuhlungu

« Emuva ku-Pipeline

I-RTX

Ubuhlungu obuhambisana ne-Arthritis yedolo

Ubuhlungu obuhlobene nomdlavuza obulalayo

I-RTX (resiniferatoxin) iyi-molecule ehlukile ye-neural intervention ekhetha kakhulu futhi ingase isetshenziswe ngokuzungezile (isb., i-nerve block, intra-articular) noma phakathi nendawo (isb, i-epidural), ukulawula ubuhlungu obungapheli kuzo zonke izimo eziningi ezihlanganisa isifo samathambo nomdlavuza.

I-RTX inamandla okuba umuthi wesigaba sokuqala esibhekana nobuhlungu obungalawuleki okwamanje ngendlela yenoveli futhi eyingqayizivele, ngokukhomba izinzwa ezinomthwalo wemfanelo wokudluliselwa kwesignali yobuhlungu obungapheli.

I-RTX ibophezela ngokuqinile kuma-receptors e-TRPV1 futhi iphoqa iziteshi ze-calcium ezivulekile ezitholakala ekugcineni kwenzwa noma i-soma ye-neuron (kuye ngokuthi umzila wokuphatha). Lokhu nakho kukhiqiza ukungena okuhamba kancane nokuqhubekayo okuholela ngokushesha ekususweni kwamaseli e-TRPV1-positive.

I-RTX ixhumana ngokuqondile namaseli ezinzwa ezihlukene ngaphandle kokuthinta izinzwa ezinjengokuthinta, ingcindezi, ubuhlungu obuhlabayo obuhlabayo, umuzwa wokudlidliza noma umsebenzi wokuxhumanisa imisipha.

Ukuphatha ekugcineni kwe-nerve ye-peripheral kubangela umphumela wesikhashana oqhubekayo wokwelapha ubuhlungu obuhambisana nakho isifo samathambo edolweni.

I-RTX ingakwazi ukusiza iziguli nge ubuhlungu bomdlavuza obungapheli, ngemva komjovo owodwa we-epidural, ngokuvimbela unomphela ukudluliswa kwesignali yobuhlungu kusuka esicutshini sethumba kuya ku-dorsal root ganglion (DRG) emgogodleni, ngaphandle kwemiphumela emibi engathandeki ehambisana nemithamo ephezulu nephindaphindiwe yama-opioid. Uma ama-opioid ehlala eyingxenye ye-arsenal yokwelapha yalezi ziguli, i-RTX inamandla okunciphisa kakhulu inani kanye nemvamisa yokusetshenziswa kwe-opioid.

I-RTX inikezwe i-Orphan Drug Status yi-US Food and Drug Administration yokwelapha izifo ezifika ekugcineni, okuhlanganisa nobuhlungu bomdlavuza obungalawuleki.

I-Sorrento igcwalise ngempumelelo ubufakazi obuhle be-Phase Ib emitholampilo yokuhlolwa komqondo ne-National Institutes of Health ngaphansi kwe-Cooperative Research and Development Agreement (CRADA) ebonise ubuhlungu obuthuthukisiwe nokunciphisa ukusetshenziswa kwe-opioid ngemva kokuphathwa kwe-intrathecal (ngqo ngqo endaweni yomgogodla).

Inkampani iqale izifundo ezibalulekile futhi ihlose ukugcwalisa i-NDA ngo-2024.